Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Advanced Solid Tumors 5Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Solid Tumor 1Rectal Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡